AR131577A1 - Compuestos moduladores del receptor de dopamina d3 / d2 - Google Patents

Compuestos moduladores del receptor de dopamina d3 / d2

Info

Publication number
AR131577A1
AR131577A1 ARP240100045A ARP240100045A AR131577A1 AR 131577 A1 AR131577 A1 AR 131577A1 AR P240100045 A ARP240100045 A AR P240100045A AR P240100045 A ARP240100045 A AR P240100045A AR 131577 A1 AR131577 A1 AR 131577A1
Authority
AR
Argentina
Prior art keywords
dopamine
modulating compounds
receptor modulating
formula
compounds
Prior art date
Application number
ARP240100045A
Other languages
English (en)
Spanish (es)
Inventor
Istvn Borza
Jnos Les
Blint Menczinger
Dek Szilvia Bodnrn
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of AR131577A1 publication Critical patent/AR131577A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ARP240100045A 2023-01-11 2024-01-09 Compuestos moduladores del receptor de dopamina d3 / d2 AR131577A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202363479530P 2023-01-11 2023-01-11

Publications (1)

Publication Number Publication Date
AR131577A1 true AR131577A1 (es) 2025-04-09

Family

ID=89573273

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240100045A AR131577A1 (es) 2023-01-11 2024-01-09 Compuestos moduladores del receptor de dopamina d3 / d2

Country Status (13)

Country Link
US (2) US12168007B1 (enExample)
EP (1) EP4400495A1 (enExample)
JP (2) JP7686096B2 (enExample)
CN (1) CN120569367A (enExample)
AR (1) AR131577A1 (enExample)
AU (1) AU2024208533A1 (enExample)
CL (1) CL2025002035A1 (enExample)
CO (1) CO2025010725A2 (enExample)
GE (1) GEAP202516807A (enExample)
IL (1) IL321654A (enExample)
MX (1) MX2025008101A (enExample)
TW (1) TW202432139A (enExample)
WO (1) WO2024150068A2 (enExample)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227534B1 (en) 2003-08-04 2011-08-29 Richter Gedeon Nyrt (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them
EP1870405A1 (en) 2006-06-22 2007-12-26 Bioprojet Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands
HUP0800765A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Nyrt A new process for the preparation of piperazine derivatives and their hydrochloric salts
US8686009B2 (en) 2009-06-25 2014-04-01 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds
WO2020156312A1 (zh) 2019-01-30 2020-08-06 江苏豪森药业集团有限公司 一种多环类衍生物调节剂、其制备方法和应用
CN118772126A (zh) 2019-10-29 2024-10-15 上海翰森生物医药科技有限公司 四元环类衍生物调节剂、其制备方法和应用
WO2021088920A1 (zh) 2019-11-05 2021-05-14 上海翰森生物医药科技有限公司 苯并噻吩类衍生物调节剂、其制备方法和应用

Also Published As

Publication number Publication date
JP7686096B2 (ja) 2025-05-30
KR20240112213A (ko) 2024-07-18
TW202432139A (zh) 2024-08-16
CN120569367A (zh) 2025-08-29
JP2024098972A (ja) 2024-07-24
JP2025122072A (ja) 2025-08-20
US12168007B1 (en) 2024-12-17
GEAP202516807A (en) 2025-08-25
US20250049786A1 (en) 2025-02-13
WO2024150068A3 (en) 2024-08-22
CL2025002035A1 (es) 2025-10-03
WO2024150068A2 (en) 2024-07-18
IL321654A (en) 2025-08-01
MX2025008101A (es) 2025-08-01
AU2024208533A1 (en) 2025-07-10
CO2025010725A2 (es) 2025-08-29
EP4400495A1 (en) 2024-07-17

Similar Documents

Publication Publication Date Title
CO2020013601A2 (es) Compuestos heterocíclicos como inmunomoduladores
AR077252A1 (es) Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
UY30641A1 (es) Derivados de 2-[1h-pirazol-5-il] y de 2-[2h-pirazol-3-il]tieno[3,2-c]piridinas sustituidas, sus sales farmaceuticamente aceptables y aplicaciones
ECSP18083519A (es) Inhibidores de bromodominios
DOP2021000198A (es) Compuestos y su uso en el tratamiento del cáncer
MX379530B (es) Compuestos agonistas del receptor muscarínico m4.
MX2022001158A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
ECSP088863A (es) Compuestos que son agonistas de receptores muscarínicos y que pueden ser eficaces en el tratamiento del dolor, la enfermedad de alzheimer y/o la esquizofrenia
MX343215B (es) Composiciones farmacéuticas del compuesto espiro-oxindol para administración tópica y sus usos como agentes terapéuticos.
ECSP088967A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
CL2009000445A1 (es) Compuestos derivados de piperidina 1,4 heterociclo sustituidos, procedimiento para preparar estos compuestos, composicion farmaceutica que los comprende y su uso para la terapia del dolor y el tratamiento de enfermedades como alzheimer, esquizofrenia, ansiedad y depresion.
CL2021000844A1 (es) Compuestos de indolinona para uso como inhibidores de map4k1
CL2022001337A1 (es) Derivados de piridopirimidinona como antagonistas de ahr
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
PE20151607A1 (es) Formulaciones de compuestos organicos
CO2018007436A2 (es) Compuestos de dihidroquinolinsulfonamida de alquilo
UY29412A1 (es) Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos.
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
CL2019003467A1 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias.
AR131577A1 (es) Compuestos moduladores del receptor de dopamina d3 / d2
CR20240216A (es) Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
ECSP088968A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
DOP2012000061A (es) Utilizacion de derivados del indol como activadores de nurr-1, para la aplicacion en tratamientos de enfermedades como el parkinson
AR131945A1 (es) Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno
UY31680A1 (es) "agonistas de los receptores muscarínicos, composiciones, métodos de tratamiento en que se emplean y sus procesos de preparación-176"